AR056445A1 - Derivados arilicos y heteroarilicos de 6 miembros para tratar virus - Google Patents

Derivados arilicos y heteroarilicos de 6 miembros para tratar virus

Info

Publication number
AR056445A1
AR056445A1 ARP060103425A ARP060103425A AR056445A1 AR 056445 A1 AR056445 A1 AR 056445A1 AR P060103425 A ARP060103425 A AR P060103425A AR P060103425 A ARP060103425 A AR P060103425A AR 056445 A1 AR056445 A1 AR 056445A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
heterocyclyl
heteroaryl
aryl
Prior art date
Application number
ARP060103425A
Other languages
English (en)
Inventor
Janos Botyanszki
Dong-Fang Shi
Christopher Don Roberts
Franz Ulrich Schmitz
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of AR056445A1 publication Critical patent/AR056445A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Composiciones y métodos para tratar infecciones por virus de la familia Flaviviridae. Reivindicacion 1: Un compuesto de formula (1), (2), o (3), caracterizado porque: B y D son, independientemente, N o C-L1-R1; con la condicion de que al menos uno de entre B o D sea N o CH; A y E son, independientemente N o C-R2; R se selecciona a partir del grupo consistente en alquilo, alquilo sustituido, cicloalquilo, cicloalquenilo, cicloalquenilo sustituido, cicloalquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, heterociclilo, heterociclilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido; R1 se selecciona a partir del grupo consistente en hidrogeno, alquilo, alquilo sustituido, cicloalquilo, cicloalquenilo, cicloalquenilo sustituido, cicloalquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, heterociclilo, heterociclilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, -COOH, -COORla, -CONR3R4 y -NR3R4; en donde cada uno de los Rla, R3, y R4 se selecciona independientemente a partr del grupo consistente en alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, heterociclilo, heterociclilo sustituido, arilo, arilo sustituido, heteroarilo, y heteroarilo sustituido; o, alternativamente, R3 y R 4 pueden estar opcionalmente unidos entre sí con el átomo de nitrogeno unido a los mismos para formar un grupo heterociclilo, heterociclilo sustituido, heteroarilo o heteroarilo sustituido; R2 se selecciona a partir del grupo consistente en hidrogeno, halogeno, alquilo C1-2, alquilo C1-2 sustituido, alquenilo C2-3, alquenilo C2-3 sustituido, ciclopropilo, y ciclopropilo sustituido; L y L1 se seleccionan independientemente a partir del grupo consistente en un enlace, alquileno C1-3, alquileno C1-3 sustituido, alquenileno C2-3, alquenileno C2-3 sustituido, alquinileno C2-3, alquinileno C2-3 sustituido, cicloalquileno C3-6, cicloalquileno C3-6 sustituido, cicloalquenileno C4-6, cicloalquenileno C4-6 sustituido, arileno, arileno sustituido, heteroarileno, y heteroarileno sustituido; Z se selecciona a partir del grupo consistente en: a) hidrogeno, halogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alcoxilo, alcoxilo sustituido, ciano, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, amino y amino sustituido; b) COOH y COOR2, en donde Rz se selecciona a partir del grupo consistente en alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, heterociclilo, heterociclilo sustituido, arilo, arilo sustituido, heteroarilo, y heteroarilo sustituido; c) -C(X1)NR5R6, en donde X1 es =O, =NH, o =N-alquilo, R5 y R6 se seleccionan independientemente a partir del grupo consistente en hidrogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterociclilo y heterociclilo sustituido o, alternativamente, R5 y R6, junto con el átomo de nitrogeno unido a ellos, forman un grupo de anillo heterociclilo, a heterociclilo sustituido, heteroarilo o heteroarilo sustituido; d) -C(X2)NR7S(O)2R8, en donde X2 se selecciona a partir de =O, =NR9, y =S, en donde R9 es hidrogeno, alquilo, o alquilo sustituido; R8 se selecciona a partir de alquilo, alquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterociclilo, heterociclilo sustituido, y NR10R11 en donde cada uno de los R7, R10, y R11 es, independientemente hidrogeno, alquilo, alquilo sustituido, cicloalquilo, o cicloalquilo sustituido, y donde cada uno de los R7 y R10 está opcionalmente sustituido con uno a tres sustituyentes seleccionados a partir del grupo consistente en halogeno, hidroxilo, carboxilo, carboxil éster, alquilo, alcoxilo, amino, y amino sustituido; o alternativamente, R7 y R10 o R10 y R11, junto con los átomos unidos a ellos, se unen entre sí para formar un grupo heterocíclico opcionalmente sustituido; e) -C(X3)-N(R12)CR13R13'C(=O)R14, en donde X3 se selecciona a partir de =O, =S, y =NR15, en donde R15 es hidrogeno o alquilo, R14 se selecciona a partir de -OR16 y -NR10R11 en donde R16 se selecciona a partir de hidrogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterociclilo y heterociclilo sustituido; R10 y R11 son los que se definio más arriba; R13 y R13' se seleccionan independientemente a partir de hidrogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, cicloalquilo, cicloalquilo sustituido, heteroarilo, heteroarilo sustituido, heterociclilo, y heterociclilo sustituido; o, alternativamente, R13 y R13' tal como se han definido se toman en conjunto con el átomo de carbono unido a ellos para formar un grupo cicloalquilo, cicloalquilo sustituido, heterociclilo o heterociclilo sustituido; o, en otra configuracion alternativa adicional, uno de los R13 o R13' es hidrogeno, alquilo o alquilo sustituido, y el otro está unido, junto al átomo de carbono unido al mismo, tanto con el R16 como con el átomo de oxígeno unido al mismo o con el R10 y el átomo de nitrogeno unido al mismo para formar un grupo heterociclilo o heterociclilo sustituido; R12 se selecciona a partir de hidrogeno y alquilo o, cuando R13 y R13' no están unidos para formar un anillo y cuando R13 o R13' y R10 o R11 no están unidos para formar un grupo heterociclilo o heterociclilo sustituido, R12, junto con el átomo de nitrogeno unido al mismo, puede tomarse junto a uno de entre R13 y R13' para formar un grupo anillo heterociclilo o heterociclilo sustituido; f) -C(X2)- N(R12)CR17R18R19, en donde X2 y R12 son los definidos más arriba, y R17, R18 y R19 son, independientemente alquilo, alquilo sustituido, arilo, arilo sustituido, heterociclilo, heterociclilo sustituido, heteroarilo y heteroarilo sustituido, o R17 y R18, junto al átomo de carbono unido a ellos, forman un grupo cicloalquilo, cicloalquilo sustituido, heterociclilo o heterociclilo sustituido; y g) un isomero carboxílico; con la condicion de que, cuando L es un enlace, Z no es hidrogeno; y Ar se selecciona a partir del grupo consistente en arilo, heteroarilo, arilo sustituido, y heteroarilo sustituido; o una sal, éster, estereoisomero, prodroga o tautomero farmacéuticamente aceptable de los mismos.
ARP060103425A 2005-08-05 2006-08-04 Derivados arilicos y heteroarilicos de 6 miembros para tratar virus AR056445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70588605P 2005-08-05 2005-08-05

Publications (1)

Publication Number Publication Date
AR056445A1 true AR056445A1 (es) 2007-10-10

Family

ID=37618699

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103425A AR056445A1 (es) 2005-08-05 2006-08-04 Derivados arilicos y heteroarilicos de 6 miembros para tratar virus

Country Status (5)

Country Link
US (1) US20070032488A1 (es)
AR (1) AR056445A1 (es)
PE (1) PE20070230A1 (es)
TW (1) TW200719898A (es)
WO (1) WO2007019397A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258116B2 (en) 2007-05-04 2012-09-04 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
BRPI0905952A2 (pt) 2008-02-04 2015-06-30 Mercury Therapeutics Composto e sais do mesmo e compição farmacêutica
WO2010096115A1 (en) 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
CN102596201A (zh) 2009-10-30 2012-07-18 贝林格尔.英格海姆国际有限公司 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案
WO2012041771A1 (en) * 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection
WO2013090929A1 (en) * 2011-12-15 2013-06-20 Gilead Sciences, Inc. Amino quinoline derivatives inhibitors of hcv
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
EA027986B9 (ru) 2012-12-20 2018-01-31 Инсепшн 2, Инк. Соединения триазолона и их применение
MX2016002795A (es) 2013-09-06 2016-05-26 Inception 2 Inc Compuestos de triazolona y usos de los mismos.
EP4159717A1 (en) 2014-10-06 2023-04-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
US10570115B2 (en) 2016-09-30 2020-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
RS61150B1 (sr) 2016-12-09 2020-12-31 Vertex Pharma Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutske kompozicije, postupci lečenja, i postupak za dobijanje modulatora
CA3066084A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AR112467A1 (es) 2017-08-02 2019-10-30 Vertex Pharma Procesos para preparar compuestos
EP3697774A1 (en) 2017-10-19 2020-08-26 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
AU2018380426B2 (en) 2017-12-08 2023-05-18 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3773577A4 (en) 2018-04-12 2021-12-01 Terns, Inc. TRICYCLIC ASK1 INHIBITORS
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
US7112601B2 (en) * 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus

Also Published As

Publication number Publication date
WO2007019397A2 (en) 2007-02-15
WO2007019397A3 (en) 2007-08-16
PE20070230A1 (es) 2007-05-30
TW200719898A (en) 2007-06-01
US20070032488A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
AR056445A1 (es) Derivados arilicos y heteroarilicos de 6 miembros para tratar virus
AR054797A1 (es) Derivados de quinolina, composicion farmaceutica que lo comprende y su uso en la preparacion de un medicamento para el tratamiento de infecciones virales por virus de la familia flaviviridae, tal como hcv.
PE20080895A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
RU2012126129A (ru) Производное индола и его фармацевтическое применение
PE20090048A1 (es) Derivados de glicina n-sustituidos: inhibidores de prolil hidroxilasa
AR077849A2 (es) Compuestos y composiciones como inhibidores de proteina quinasa
CL2020001919A1 (es) Inhibidores de endonucleasa cap-dependientes.
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
RU2009115963A (ru) Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
AR052330A1 (es) Derivados de adamantano que comprenden quinoleinas sustituidas
CO5680430A2 (es) Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis
TNSN06203A1 (en) Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
AR062258A1 (es) Compuestos heterociclicos condensados de tieno-pirrol, composiciones farmaceuticas que los contienen y usos para el tratamiento de infecciones por hcv
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure